147 related articles for article (PubMed ID: 31343218)
1. Nonadherence to tamoxifen in breast cancer survivors: A 12 month longitudinal analysis.
Moon Z; Moss-Morris R; Hunter MS; Norton S; Hughes LD
Health Psychol; 2019 Oct; 38(10):888-899. PubMed ID: 31343218
[TBL] [Abstract][Full Text] [Related]
2. More than just side-effects: The role of clinical and psychosocial factors in non-adherence to tamoxifen.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):998-1018. PubMed ID: 28940998
[TBL] [Abstract][Full Text] [Related]
3. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
[TBL] [Abstract][Full Text] [Related]
4. Psychosocial factors in adjuvant hormone therapy for breast cancer: an emerging context for adherence research.
Van Liew JR; Christensen AJ; de Moor JS
J Cancer Surviv; 2014 Sep; 8(3):521-31. PubMed ID: 24986227
[TBL] [Abstract][Full Text] [Related]
5. Five-Year Adjuvant Endocrine Therapy Adherence Trajectories Among Women With Breast Cancer: A Nationwide French Study Using Administrative Data.
Lailler G; Memoli V; Le Bihan Benjamin C; Ben Diane MK; Lauzier S; Mancini J; Bousquet PJ; Bouhnik AD
Clin Breast Cancer; 2021 Aug; 21(4):e415-e426. PubMed ID: 33745868
[TBL] [Abstract][Full Text] [Related]
6. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
Paranjpe R; John G; Trivedi M; Abughosh S
Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
[TBL] [Abstract][Full Text] [Related]
7. Serum Detection of Nonadherence to Adjuvant Tamoxifen and Breast Cancer Recurrence Risk.
Pistilli B; Paci A; Ferreira AR; Di Meglio A; Poinsignon V; Bardet A; Menvielle G; Dumas A; Pinto S; Dauchy S; Fasse L; Cottu PH; Lerebours F; Coutant C; Lesur A; Tredan O; Soulie P; Vanlemmens L; Jouannaud C; Levy C; Everhard S; Arveux P; Martin AL; Dima A; Lin NU; Partridge AH; Delaloge S; Michiels S; André F; Vaz-Luis I
J Clin Oncol; 2020 Aug; 38(24):2762-2772. PubMed ID: 32568632
[TBL] [Abstract][Full Text] [Related]
8. Predicting nonadherence to adjuvant endocrine therapy in women with early stage breast cancer.
Corter AL; Broom R; Porter D; Harvey V; Findlay M
Psychooncology; 2018 Sep; 27(9):2096-2103. PubMed ID: 29776011
[TBL] [Abstract][Full Text] [Related]
9. Development of a self-management intervention to improve tamoxifen adherence in breast cancer survivors using an Intervention Mapping framework.
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Support Care Cancer; 2021 Jun; 29(6):3329-3338. PubMed ID: 33118106
[TBL] [Abstract][Full Text] [Related]
10. Perceived barriers to treatment predict adherence to aromatase inhibitors among breast cancer survivors.
Brier MJ; Chambless DL; Gross R; Chen J; Mao JJ
Cancer; 2017 Jan; 123(1):169-176. PubMed ID: 27570979
[TBL] [Abstract][Full Text] [Related]
11. Beliefs About Medication and Uptake of Preventive Therapy in Women at Increased Risk of Breast Cancer: Results From a Multicenter Prospective Study.
Thorneloe RJ; Horne R; Side L; Wolf MS; Smith SG;
Clin Breast Cancer; 2019 Feb; 19(1):e116-e126. PubMed ID: 30518498
[TBL] [Abstract][Full Text] [Related]
12. The relationship between risk factors and medication adherence among breast cancer survivors: What explanatory role might depression play?
Markovitz LC; Drysdale NJ; Bettencourt BA
Psychooncology; 2017 Dec; 26(12):2294-2299. PubMed ID: 28032940
[TBL] [Abstract][Full Text] [Related]
13. Barriers to and facilitative processes of endocrine therapy adherence among women with breast cancer.
Bright EE; Petrie KJ; Partridge AH; Stanton AL
Breast Cancer Res Treat; 2016 Jul; 158(2):243-51. PubMed ID: 27342455
[TBL] [Abstract][Full Text] [Related]
14. Contributors to nonadherence and nonpersistence with endocrine therapy in breast cancer survivors recruited from an online research registry.
Stanton AL; Petrie KJ; Partridge AH
Breast Cancer Res Treat; 2014 Jun; 145(2):525-34. PubMed ID: 24781972
[TBL] [Abstract][Full Text] [Related]
15. Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.
Lambert LK; Balneaves LG; Howard AF; Chia SK; Gotay CC
BMC Cancer; 2018 Jul; 18(1):732. PubMed ID: 29996816
[TBL] [Abstract][Full Text] [Related]
16. Intentional and unintentional nonadherence to ocular hypotensive treatment in patients with glaucoma.
Rees G; Leong O; Crowston JG; Lamoureux EL
Ophthalmology; 2010 May; 117(5):903-8. PubMed ID: 20153902
[TBL] [Abstract][Full Text] [Related]
17. Prospective investigation of social support, coping, and depressive symptoms: A model of adherence to endocrine therapy among women with breast cancer.
Bright EE; Stanton AL
J Consult Clin Psychol; 2018 Mar; 86(3):242-253. PubMed ID: 29265835
[TBL] [Abstract][Full Text] [Related]
18. Medication nonadherence in Korean patients with rheumatoid arthritis: the importance of belief about medication and illness perception.
Suh YS; Cheon YH; Kim HO; Kim RB; Park KS; Kim SH; Lee SG; Park EK; Hur J; Lee SI
Korean J Intern Med; 2018 Jan; 33(1):203-210. PubMed ID: 28859470
[TBL] [Abstract][Full Text] [Related]
19. Measuring illness representations in breast cancer survivors (BCS) prescribed tamoxifen: Modification and validation of the Revised Illness Perceptions Questionnaire (IPQ-BCS).
Moon Z; Moss-Morris R; Hunter MS; Hughes LD
Psychol Health; 2017 Apr; 32(4):439-458. PubMed ID: 28052692
[TBL] [Abstract][Full Text] [Related]
20. Intentional and unintentional treatment nonadherence in patients with systemic lupus erythematosus.
Daleboudt GM; Broadbent E; McQueen F; Kaptein AA
Arthritis Care Res (Hoboken); 2011 Mar; 63(3):342-50. PubMed ID: 21120967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
